The trajectory of companies tied to Viagra's past presents a challenging investment scenario . While the initial boom generated substantial gains, generic alternatives have significantly diminished market share . Investing in associated pharmaceutical firms now requires a careful assessment of intellectual property safeguards, evolving healthcare s